Outputs (62)

SPHINX-based combination therapy as a potential novel treatment strategy for acute myeloid leukaemia (2023)
Journal Article
Wodi, C., Belali, T., Morse, R., Porazinski, S., & Ladomery, M. (2023). SPHINX-based combination therapy as a potential novel treatment strategy for acute myeloid leukaemia. British Journal of Biomedical Science, 80, 11041. https://doi.org/10.3389/bjbs.2023.11041

Introduction: Dysregulated alternative splicing is a prominent feature of cancer. The inhibition and knockdown of the SR splice factor kinase SRPK1 reduces tumour growth in vivo. As a result several SPRK1 inhibitors are in development including SPHIN... Read More about SPHINX-based combination therapy as a potential novel treatment strategy for acute myeloid leukaemia.

CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer (2021)
Journal Article
Uzor, S., Porazinski, S., Li, L., Clark, B., Ajiro, M., Iida, K., …Ladomery, M. (2021). CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer. Scientific Reports, 11(1), Article 7963. https://doi.org/10.1038/s41598-021-86908-6

Dysregulation of alternative splicing is a feature of cancer, both in aetiology and progression. It occurs because of mutations in splice sites or sites that regulate splicing, or because of the altered expression and activity of splice factors and o... Read More about CDC2-like (CLK) protein kinase inhibition as a novel targeted therapeutic strategy in prostate cancer.

Epigenenetic regulation of alternative splicing: How lncRNAs tailor the message (2021)
Journal Article
Pisignano, G., & Ladomery, M. (2021). Epigenenetic regulation of alternative splicing: How lncRNAs tailor the message. Non-Coding RNA, 7(1), Article 21. https://doi.org/10.3390/ncrna7010021

Alternative splicing is a highly fine-tuned regulated process and one of the main drivers of proteomic diversity across eukaryotes. The vast majority of human multi-exon genes is alternatively spliced in a cell type-and tissue-specific manner, and de... Read More about Epigenenetic regulation of alternative splicing: How lncRNAs tailor the message.

WT1 activates transcription of the splice factor kinase SRPK1 gene in PC3 and K562 cancer cells in the absence of corepressor BASP1 (2020)
Journal Article
Belali, T., Wodi, C., Clark, B., Cheung, M. K., Craig, T. J., Wheway, G., …Ladomery, M. (2020). WT1 activates transcription of the splice factor kinase SRPK1 gene in PC3 and K562 cancer cells in the absence of corepressor BASP1. BBA - Gene Regulatory Mechanisms, 1863(12), Article 194642. https://doi.org/10.1016/j.bbagrm.2020.194642

Dysregulated alternative splicing plays a prominent role in all hallmarks of cancer. The splice factor kinase SRPK1 drives the activity of oncogenic splice factors such as SRSF1. SRSF1 in turn promotes the expression of splice isoforms that favour tu... Read More about WT1 activates transcription of the splice factor kinase SRPK1 gene in PC3 and K562 cancer cells in the absence of corepressor BASP1.

Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer (2020)
Journal Article
Li, L., Hobson, L., Perry, L., Clark, B., Heavey, S., Haider, A., …Ladomery, M. (2020). Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer. British Journal of Cancer, 123, 1024-1032. https://doi.org/10.1038/s41416-020-0951-2

Background: The ERG oncogene, a member of the ETS family of transcription factor encoding genes, is a genetic driver of prostate cancer. It is activated through a fusion with the androgen-responsive TMPRSS2 promoter in 50% of cases. There is therefor... Read More about Targeting the ERG oncogene with splice-switching oligonucleotides as a novel therapeutic strategy in prostate cancer.

APC and AXIN2 are promising biomarker candidates for the early detection of adenomas and hyperplastic polyps (2020)
Journal Article
Almond, S., Anaraki, F., Young, C., Ashrafian Bonab, M., Asadzadeh-Aghdaei, H., Rezvani, H., …Ladomery, M. (2020). APC and AXIN2 are promising biomarker candidates for the early detection of adenomas and hyperplastic polyps. Cancer Informatics, 19, 1-8. https://doi.org/10.1177/1176935120972383

Aberrant activation of the WNT/CTNNB1 pathway is notorious in colorectal cancer (CRC). Here, we demonstrate that the expression of specific and crucial WNT signaling pathway genes is linked to disease progression in colonic adenomatous (AP) and hyper... Read More about APC and AXIN2 are promising biomarker candidates for the early detection of adenomas and hyperplastic polyps.

Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment (2019)
Journal Article
Koschorke, A., Faraci, S., Giani, D., Chiodoni, C., Iorio, E., Canese, R., …Pupa, S. M. (2019). Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment. Cellular Oncology, 42(6), 815-828. https://doi.org/10.1007/s13402-019-00464-w

© 2019, International Society for Cellular Oncology. Purpose: Isothiocyanates elicit anticancer effects by targeting cancer stem cells (CSCs). Here, we tested the antitumor activity of phenethyl-isothiocyanate (PEITC), either alone or in combination... Read More about Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment.

Investigating ROS, RNS, and H2S-sensitive signaling proteins (2019)
Book Chapter
Williams, E., Whiteman, M., Wood, M. E., Wilson, I. D., Ladomery, M. R., Allainguillaume, J., …Hancock, J. T. (2019). Investigating ROS, RNS, and H2S-sensitive signaling proteins. In J. T. Hancock, & M. E. Conway (Eds.), Redox-Mediated Signal Transduction (27-42). Humana, New York, NY. https://doi.org/10.1007/978-1-4939-9463-2_3

© Springer Science+Business Media, LLC, part of Springer Nature 2019. The modification of proteins is a key way to alter their activity and function. Often thiols, cysteine residues, on proteins are attractive targets for such modification. Assuming... Read More about Investigating ROS, RNS, and H2S-sensitive signaling proteins.

Altered VEGF splicing isoform balance in tumor endothelium involves activation of splicing factors Srpk1 and Srsf1 by the Wilms’ tumor suppressor Wt1 (2019)
Journal Article
Ladomery, M. (2019). Altered VEGF splicing isoform balance in tumor endothelium involves activation of splicing factors Srpk1 and Srsf1 by the Wilms’ tumor suppressor Wt1. Cells, 8(1), 41. https://doi.org/10.339010.3390/cells8010041

Angiogenesis is one hallmark of cancer. Vascular endothelial growth factor (VEGF) is a known inducer of angiogenesis. Many patients benefit from antiangiogenic therapies, which however have limitations. Although VEGF is overexpressed in most tumors,... Read More about Altered VEGF splicing isoform balance in tumor endothelium involves activation of splicing factors Srpk1 and Srsf1 by the Wilms’ tumor suppressor Wt1.

The Evolutionarily Conserved Cassette Exon 7b Drives ERG's Oncogenic Properties (2018)
Journal Article
Jumbe, S., Porazinski, S., Oltean, S., Mansell, J., Vahabi, B., Wilson, I., & Ladomery, M. (2019). The Evolutionarily Conserved Cassette Exon 7b Drives ERG's Oncogenic Properties. Translational Oncology, 12(1), 134-142. https://doi.org/10.1016/j.tranon.2018.09.001

© 2018 The oncogene ERG encodes an ETS family transcription factor and is implicated in blood, vascular, and bone development and in prostate, blood, and bone cancer. The ERG gene is alternatively spliced; of particular interest is its cassette exon... Read More about The Evolutionarily Conserved Cassette Exon 7b Drives ERG's Oncogenic Properties.